NCT04594798 : Clinical Trial Detail - Cancer Knowledgebase (CKB)

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

NCT ID	NCT04594798
Title	A Study of Polatuzumab Vedotin, Rituximab and Dose Attenuated CHP in Older Patients With DLBCL
Recruitment	Recruiting
Gender	both
Phase	Phase II
Variant Requirements	No
Sponsors	University of Rochester
Indications	diffuse large B-cell lymphoma follicular lymphoma B-cell lymphoma
Therapies	Cyclophosphamide + Doxorubicin + Polatuzumab vedotin-piiq + Prednisone + Rituximab
Age Groups:	senior
Covered Countries	USA

Filter rows:

Showing 1 to 1 of 1 entries

Facility	Status	City	State	Zip	Country	Details
University of Rochester	RECRUITING	Rochester	New York	14642	United States	Details

Showing 1 to 1 of 1 entries

Filter rows:

*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field

NCT04594798Clinical Trial Detail